ClinicalTrials.gg
Not yet recruitingNCT07862634Updated Oct 7, 2026

A Trial of AGMB-447 in Participants With Idiopathic Pulmonary Fibrosis

A Phase 2 interventional study of AGMB-447 and Placebo in Idiopathic Pulmonary Fibrosis (IPF), sponsored by Agomab Spain S.L.U.. Not yet recruiting. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Agomab Spain S.L.U. (part of Agomab Therapeutics NV) · Phase 2, Interventional, and Treatment

Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

The main goal of this clinical trial is to find out if an experimental inhaled drug, AGMB-447, can help improve lung function in people living with a lung disease called idiopathic pulmonary fibrosis (IPF). To do this, the effects of the study drug will be compared to a placebo, which is a treatment that looks like the study drug but contains no active medicine.

The specific goals of the trial are as follows:

Primary Objective and Estimand: The main goal is to see if 24 weeks of treatment with AGMB-447 helps the lungs work better than a placebo. This is measured by checking the total amount of air a person can forcefully blow out after taking a deep breath. The study will measure this effect for all participants who start the trial, regardless of whether they are able to finish the full 24 weeks of treatment or if they need to change their other medications during the study.

Secondary Objective: The trial also aims to measure how much of the study drug is in the blood at different times. This helps researchers understand how the drug is absorbed and processed by the body after it is inhaled. In addition, the trial aims to evaluate if the treatment is safe and well-tolerated.

Read the detailed description

This is a double-blind, randomized, placebo-controlled, multicenter Phase 2a trial to assess efficacy, safety, tolerability and pharmacokinetics (PK) of AGMB-447 compared to placebo in participants diagnosed with IPF over 24 weeks of treatment. The trial population will include adult participants aged ≥40 years with a confirmed diagnosis of IPF.

Approximately 120 eligible participants will be randomized in a 2:1 ratio to AGMB-447 or placebo group. Both AGMB-447 and placebo will be administered via inhalation.

The total duration of the trial for each participant will be up to approximately 32 weeks, consisting of a 4-week screening period, a 24-week treatment period, and a 4-week follow-up period.

After written informed consent is obtained, participants will enter a screening period of up to 28 days to assess eligibility.

Participants on an approved antifibrotic treatment should be on a stable dose for at least 8 weeks before the screening visit and throughout the screening period; or participants who are not on antifibrotic treatment should be stable for at least 4 weeks before the screening visit (treatment-naïve or intolerant).

At the end of the Treatment period, participants will enter a 4-week Follow-up period. The last trial visit (End of Study) for all participants will be on site, at the end of the Follow-up period.

Throughout the study, participants will undergo routine safety assessments at study visits, which will include physical examination, vital signs, clinical laboratory assessments, electrocardiogram (ECG), and recording of AEs.

02

Conditions studied

  • Idiopathic Pulmonary Fibrosis (IPF)
03

In context

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 122 are open to participants now.

This study's planned enrollment of 120 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.

Browse Idiopathic Pulmonary Fibrosis studies →

Lead sponsor

Agomab Spain S.L.U. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

First submitted after Agomab Spain S.L.U. became part of Agomab Therapeutics NV.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged ≥40 years at the time of signing the ICF.
  • Diagnosis of IPF within 7 years prior to the screening visit, confirmed by centrally reviewed high-resolution computed tomography (HRCT) of the chest (performed during screening period).
  • Confirmed pulmonary function criteria at screening, as follows:

    1. FVC ≥45% predicted of normal, as determined by spirometry,
    2. /FVC >0.7 or LLN, as determined by spirometry,
    3. Diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for ≥25% predicted of normal
  • On standard of care for the treatment of IPF at a stable dose for at least 8 weeks before the screening visit, and during the screening period; or not on antifibrotic treatment and stable for at least 4 weeks before the screening visit (naïve or intolerant).
  • Women of non (WONCBP) or male participants willing to comply with this protocol's requirements regarding .

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of fibrosing interstitial lung disease other than IPF.
  • Acute IPF exacerbation within 6 months prior to screening and/or during the screening period.
  • Lower respiratory tract infection requiring treatment within 4 weeks prior to screening and/or during the screening period.
  • History of lung volume reduction surgery or lung transplant or major surgery performed within 3 months prior to baseline or planned during the trial (being on a transplant list is allowed).
  • Systemic or opportunistic infections including:

    1. Active infection with .
    2. Known current tuberculosis infection.
    3. Positive for surface antigen (HBsAg) or hepatitis B core antibody (HBcAb).
    4. Chronic (positive hepatitis C virus antibody [HCVAb] and hepatitis C virus [HCV] RNA).
  • Concurrent or previous participation in another clinical trial and received therapy within 4 weeks or 5 half-lives (whichever is longer) prior to screening.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    AGMB-447

    Drug: AGMB-447

  • Experimental
    Placebo

    Matching Placebo

    Drug: Placebo

Interventions

  • DrugAGMB-447

    Administered via inhalation

  • DrugPlacebo

    Matching placebo administered via inhalation

06

What researchers measure

Primary outcomes

  1. Change in Forced Vital Capacity (FVC) (mL)

    To evaluate the effect of AGMB-447 on lung function in participants with IPF, compared to placebo

    Time frame: At week 24 compared to baseline (Day 1)

Secondary outcomes

  1. Concentration of AGMB-447 and MET-093 metabolite in plasma

    To characterize the systemic PK of AGMB-447 in participants with IPF

    Time frame: From baseline to week 24

  2. Incidence of Treatment Emergent Adverse Events (TEAEs)

    To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo

    Time frame: From baseline to week 24

  3. Number of participants with abnormal clinical laboratory tests

    To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo

    Time frame: From baseline to week 24

  4. Number of participants with abnormal ECG parameters

    To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo

    Time frame: From baseline to week 24

  5. Number of participants with abnormal vital signs

    To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo

    Time frame: From baseline to week 24

  6. Number of participants with abnormal physical examinations

    To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo

    Time frame: From baseline to week 24

  7. Change in forced expiratory volume in 1 second (FEV1)

    To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo

    Time frame: From pre-dose to week 24

  8. Change in forced expiratory volume in 1 second (FEV1)/ forced vital capacity (FVC)

    To evaluate the safety and tolerability of AGMB-447 in participants with IPF, compared to placebo

    Time frame: From pre-dose to week 24

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2028, 23 months later.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 45. This study's planned 23 months is below that.

Counting every sponsor, half of 76 studies reached it within 29 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Oct 7, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Oct 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07862634
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Oct 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Agomab Clinical Operations
Contact
clinicalstudies@agomab.com
0032 3318 91 70
Kay Tetzlaff, MD
study director · Agomab Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion